Prothena Corporation plc (PRTA)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 21.34 |
| Open | 21.61 |
| Bid | 21.00 x 100 |
| Ask | 21.05 x 200 |
| Day's range | 20.95 - 21.70 |
| 52-week range | 20.95 - 79.65 |
| Volume | |
| Avg. volume | 674,525 |
| Market cap | 1.128B |
| Beta (5Y monthly) | 0.24 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.76 |
| Earnings date | 29 Apr 2024 - 03 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 66.77 |
Business WireProthena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma
DUBLIN, April 15, 2024--Prothena today announced a publication related to the mechanism of action, pharmacological characteristics, and clinical utility of birtamimab.
Investor's Business DailyRace To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
The Alzheimer's treatment space is heating up — and could soon leave Eli Lilly's embattled drug, donanemab, in the dust, experts say.
ZacksCHMP to Delay Nod on Biogen (BIIB), Eisai's Alzheimer's Drug
Per Biogen (BIIB)/Eisai, the delay in CHMP recommendation for lecanemab is entirely related to procedural reasons at the EMA and is not related to the companies' regulatory filing.
© 2024 Yahoo. All rights reserved.